UPDATE: Regeneron Reports Two-Year Results from Phase 3 VISTA Trail of Eylea, Says Showed Sustained Improvement in Vision

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Bayer HealthCare today announced that in the Phase 3 VISTA-DME trial of EYLEA^® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained